Chowdhary M, et al. – In this study, researchers evaluated data from 26 patients (2008-2016) to assess the improved effectiveness and reduced toxicity of neoadjuvant interdigitated chemoradiotherapy by using mesna, doxorubicin, and ifosfamide for large, high-grade, soft tissue sarcomas of the limbs. They noted 88.5% of patients were still alive after a median follow-up of 47.3 months. They observed 95.0%, 64.0%, and 95.0% as the 3-year locoregional recurrence-free survival, disease-free survival, and overall survival rates, respectively. A non-hematologic grade 4 toxicity rate of 7.7% was recorded, suggesting acceptable and manageable toxicity and highly favorable survival in those at greatest risk for treatment failure.